NIR-IIb fluorescence-image guided synergistic surgery/ starvation/chemodynamic therapy: an innovative treatment paradigm for malignant non-small cell lung cancers

Han，Xuejiao1,2; Zhong，Yingtao2; Mi，Chao3; He，Zhiguo2; Gu，Jingsi4; Dai，Xiaoyong5; Ma，Chenguang3; Feng，Chunyan5; Chen，Huaqing5; Lan，Zebin2; Guo，Zhiyong3; Huang，Laiqiang5; Zhang，Baozhu6; Guo，Bing2; Meng，Qingwei1

2023

10.7150/thno.83753

Theranostics   影响因子和分区

1838-7640

1838-7640

Background: Currently, the prognosis and survival rate for patients bearing non-small cell lung cancer (NSCLC) is still quite poor, mainly due to lack of efficient theranostic paradigms to exert in time diagnostics and therapeutics. Methods: Herein, for NSCLC treatment, we offer a customized theranostic paradigm, termed NIR-IIb fluorescence diagnosis and synergistic surgery/starvation/chemodynamic therapeutics, with a newly designed theranostic nanoplatform PEG/MnCuDCNPs@GOx. The nanoplatform is composed of brightly NIR-II emissive downconversion nanoparticles (DCNPs)-core and Mn/Cu-silica shell loaded with glucose oxidase (GOx) to achieve synergistic starvation and chemodynamic therapy (CDT). Results: It is found that 10% Ce3+ doped in the core and 100% Yb3+ doped in the middle shell greatly improves the NIR-IIb emission up to even 20.3 times as compared to the core-shell DCNPs without Ce3+ doping and middle shell. The bright NIR-IIb emission of the nanoplatform contributes to sensitive margin delineation of early-stage NSCLC (diameter < 1 mm) with a signal-to-background ratio (SBR) of 2.18, and further assists in visualizing drug distribution and guiding surgery/starvation/chemodynamic therapy. Notably, the starvation therapy mediated by GOx-driven oxidation reaction efficiently depletes intratumoral glucose, and supplies H2O2 to boost the CDT mediated by the Mn2+ and Cu2+, which consequently realized a highly effective synergistic treatment for NSCLC. Conclusion: This research demonstrates an efficient treatment paradigm for NSCLC with NIR-IIb fluorescence diganosis and image-guided synergistic surgery/starvation/chemodynamic therapeutics.

chemodynamic therapy downconversion nanoparticles early tumors NIR-II fluorescence imaging non-small cell lung cancers

SCI

英语

其他

Basic and Applied Basic Research Foundation of Guangdong Province[2021A1515110086];Harbin Institute of Technology[HA11409049];Harbin Institute of Technology[HA45001108];

Research & Experimental Medicine

Medicine, Research & Experimental

WOS:000994216000008

IVYSPRING INT PUBL

2-s2.0-85156180797

Scopus

1.Department of Medical Oncology,Harbin Medical University Cancer Hospital,Harbin,150081,China
2.School of Science,Shenzhen Key Laboratory of Flexible Printed Electronics Technology,Harbin Institute of Technology,Shenzhen,518055,China
3.UTS-SUStech Joint Research Centre for Biomedical Materials and Devices,Department of Biomedical Engineering,Southern University of Science and Technology,Shenzhen,Guangdong,518055,China
4.Education Center and Experiments and Innovations,Harbin Institute of Technology,Shenzhen,518055,China
5.Institute of Biopharmaceutical and Health Engineering,Shenzhen Key Laboratory of Gene and Antibody Therapy,State Key Laboratory of Chemical Oncogenomics,Shenzhen International Graduate School,Tsinghua University,Shenzhen,Guangdong,518055,China
6.Department of Radiation Oncology,People's Hospital of Shenzhen Baoan District,The Second Affiliated Hospital of Shenzhen University,Shenzhen,Guangdong,518100,China

Han，Xuejiao,Zhong，Yingtao,Mi，Chao,et al. NIR-IIb fluorescence-image guided synergistic surgery/ starvation/chemodynamic therapy: an innovative treatment paradigm for malignant non-small cell lung cancers[J]. Theranostics,2023,13(7):2176-2191.

Han，Xuejiao.,Zhong，Yingtao.,Mi，Chao.,He，Zhiguo.,Gu，Jingsi.,...&Meng，Qingwei.(2023).NIR-IIb fluorescence-image guided synergistic surgery/ starvation/chemodynamic therapy: an innovative treatment paradigm for malignant non-small cell lung cancers.Theranostics,13(7),2176-2191.

Han，Xuejiao,et al."NIR-IIb fluorescence-image guided synergistic surgery/ starvation/chemodynamic therapy: an innovative treatment paradigm for malignant non-small cell lung cancers".Theranostics 13.7(2023):2176-2191.